KIF5A upregulation in hepatocellular carcinoma: A novel prognostic biomarker associated with unique tumor microenvironment status
Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a mic...
Saved in:
| Published in | Frontiers in oncology Vol. 12; p. 1071722 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
06.01.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen
via
MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC. |
|---|---|
| AbstractList | Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen
via
MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC. Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC. Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen via MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC.Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen via MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC. Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential biomarker that is capable of accurately predicting the prognosis and therapeutic response of LIHC. Kinesin family member 5A (KIF5A) is a microtubule-based motor protein involved in the transport of macromolecules such as organelle proteins in cells. Recent studies have illustrated that the high expression of KIF5A was related to poor prognosis of solid tumors, including bladder cancer, prostate cancer, and breast cancer. However, little is currently known concerning the clinical significance of KIF5A expression in LIHC. Herein, by adopting multi-omics bioinformatics analysis, we comprehensively uncovered the potential function and the predictive value of KIF5A in stratifying clinical features among patients with LIHC, for which a high KIF5A level predicted an unfavorable clinical outcome. Results from KIF5A-related network and enrichment analyses illustrated that KIF5A might involve in microtubule-based process, antigen processing and presentation of exogenous peptide antigen via MHC class II. Furthermore, immune infiltration and immune function analyses revealed upregulated KIF5A could predict a unique tumor microenvironment with more CD8+T cells and a higher level of anti-tumor immune response. Evidence provided by immunohistochemistry staining (IHC) further validated our findings at the protein level. Taken together, KIF5A might serve as a novel prognostic biomarker for predicting immunotherapy response and could be a potential target for anti-cancer strategies for LIHC. |
| Author | Chen, Xue-min Liu, Hao-run Xu, Chang-tao Li, Hao Tao, Bing-yan Chen, Kuang Shi, Ying Li, Wei-min Liu, Yu-yang Liu, Qi |
| AuthorAffiliation | 1 Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center, Chinese PLA General Hospital , Beijing , China 4 Senior Department of Otolaryngology-Head & Neck Surgery, Chinese PLA General Hospital , Beijing , China 5 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China 2 Department of Hepatobiliary, The Eighth Medical Center, Chinese PLA General Hospital , Beijing , China 3 Medical School of Chinese PLA , Beijing , China 6 Department of Neurobiology, Beijing Institute of Basic Medical Sciences , Beijing , China |
| AuthorAffiliation_xml | – name: 5 School of Medicine, University of Electronic Science and Technology of China , Chengdu , China – name: 6 Department of Neurobiology, Beijing Institute of Basic Medical Sciences , Beijing , China – name: 4 Senior Department of Otolaryngology-Head & Neck Surgery, Chinese PLA General Hospital , Beijing , China – name: 1 Faculty of Hepato-Pancreato-Biliary Surgery, The First Medical Center, Chinese PLA General Hospital , Beijing , China – name: 2 Department of Hepatobiliary, The Eighth Medical Center, Chinese PLA General Hospital , Beijing , China – name: 3 Medical School of Chinese PLA , Beijing , China |
| Author_xml | – sequence: 1 givenname: Qi surname: Liu fullname: Liu, Qi – sequence: 2 givenname: Yu-yang surname: Liu fullname: Liu, Yu-yang – sequence: 3 givenname: Xue-min surname: Chen fullname: Chen, Xue-min – sequence: 4 givenname: Bing-yan surname: Tao fullname: Tao, Bing-yan – sequence: 5 givenname: Kuang surname: Chen fullname: Chen, Kuang – sequence: 6 givenname: Wei-min surname: Li fullname: Li, Wei-min – sequence: 7 givenname: Chang-tao surname: Xu fullname: Xu, Chang-tao – sequence: 8 givenname: Ying surname: Shi fullname: Shi, Ying – sequence: 9 givenname: Hao surname: Li fullname: Li, Hao – sequence: 10 givenname: Hao-run surname: Liu fullname: Liu, Hao-run |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36686769$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kktvEzEQx1eoiJbSD8AF-cglwc_1mgNSVNESUYkLSNwsrx-Jy6692N4gjnzzOk2KWiR8sTWP33hm_i-bkxCDbZrXCC4J6cQ7F4NeYojxEkGOOMbPmjOMCV0ISr6fPHqfNhc538J6WgYRJC-aU9K2Xctbcdb8-by-YiswT8lu5kEVHwPwAWztpErUdhiqMQGtkvYhjuo9WIEQd3YAU4qbEHPxGvS-etIPm4DKOWqvijXgly9bMAf_c7agzGNMYPQ6RRt2PsUw2lBALqrM-VXz3Kkh24vjfd58u_r49fLT4ubL9fpydbPQtGVloTvmOmOswo4a2nPcIW2ZQ8xwgmjLlWAcOUs5w5hWh0AY95AJhXDvlO7JebM-cE1Ut3JKvv75t4zKy3tDTBupUm1nsLLvoUYUcWSYoaJ1QjluhIKYcyqE0pX14cCa5n60RtdukhqeQJ96gt_KTdxJ0bG6PFoBb4-AFOuEcpGjz_txq2DjnCXmbdchQgSvoW8e1_pb5GGHNYAfAup4c07WSe3L_SZraT9IBOVeMHIvGLkXjDwKpmaifzIf4P_PuQOvKsgK |
| CitedBy_id | crossref_primary_10_1111_crj_70020 crossref_primary_10_1007_s12032_024_02497_0 crossref_primary_10_1038_s41416_024_02829_x crossref_primary_10_3724_abbs_2024082 |
| Cites_doi | 10.1016/j.cell.2018.02.052 10.1158/2159-8290.CD-15-1545 10.1136/jitc-2019-000394 10.1186/s13059-016-1070-5 10.1093/nar/gky311 10.3748/wjg.v25.i14.1653 10.1007/s11912-020-0875-2 10.1073/pnas.1319848111 10.1007/s00262-020-02711-8 10.1083/jcb.200301026 10.1016/j.bbcan.2021.188615 10.1038/s41568-021-00339-z 10.1200/JCO.2015.61.1509 10.1158/1541-7786.MCR-13-0459 10.1158/0008-5472.CAN-15-0255 10.3390/cancers13092164 10.1038/s41598-021-84787-5 10.1016/j.soc.2019.02.001 10.3389/fonc.2021.716844 10.1155/2019/4824902 10.1007/978-1-0716-0327-7_17 10.3390/ijms22115801 10.1038/s41572-020-00240-3 10.1007/s00270-015-1208-y 10.1016/j.it.2016.08.010 10.1038/s41388-020-01519-1 10.1016/j.immuni.2019.08.004 10.7150/jca.48983 10.1093/bib/bbac129 10.1038/nmeth.1607 10.1146/annurev-med-090514-013832 10.1016/j.eururo.2012.11.053 10.3389/fcell.2021.743046 10.1111/resp.12789 10.1016/S0140-6736(18)30207-1 10.1093/nar/gkaa1074 10.1016/S0140-6736(16)32453-9 10.1016/j.smim.2020.101386 10.1152/physrev.00023.2007 10.1056/NEJMra1713263 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu. Copyright © 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu |
| Copyright_xml | – notice: Copyright © 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu. – notice: Copyright © 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fonc.2022.1071722 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_bb0c14171d5d496f9af7d9a0277499ac PMC9853384 36686769 10_3389_fonc_2022_1071722 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-c85f8ddea2f4d4b7281ce5f15d731467a9571fe475224e5f9122b059a12bfacb3 |
| IEDL.DBID | M48 |
| ISSN | 2234-943X |
| IngestDate | Wed Aug 27 01:30:34 EDT 2025 Thu Aug 21 18:38:47 EDT 2025 Fri Jul 11 13:31:01 EDT 2025 Thu Jan 02 22:55:28 EST 2025 Thu Apr 24 22:59:12 EDT 2025 Tue Jul 01 02:57:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | prognostic biomarker liver hepatocellular carcinoma tumor microenvironment KIF5A immunotherapy |
| Language | English |
| License | Copyright © 2023 Liu, Liu, Chen, Tao, Chen, Li, Xu, Shi, Li and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-c85f8ddea2f4d4b7281ce5f15d731467a9571fe475224e5f9122b059a12bfacb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Chen Qu, Jinan University, China This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology These authors have contributed equally to this work Reviewed by: Xiaobing Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Lu He, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, China |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2022.1071722 |
| PMID | 36686769 |
| PQID | 2768813397 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bb0c14171d5d496f9af7d9a0277499ac pubmedcentral_primary_oai_pubmedcentral_nih_gov_9853384 proquest_miscellaneous_2768813397 pubmed_primary_36686769 crossref_citationtrail_10_3389_fonc_2022_1071722 crossref_primary_10_3389_fonc_2022_1071722 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-06 |
| PublicationDateYYYYMMDD | 2023-01-06 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in oncology |
| PublicationTitleAlternate | Front Oncol |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Ferris (B10) 2015; 33 Marengo (B3) 2016; 67 Xia (B19) 2003; 161 Lin (B29) 2022; 23 Rock (B34) 2016; 37 Rothermel (B6) 2019; 28 Liu (B23) 2018; 173 Hirokawa (B18) 2008; 88 Bruix (B15) 2017; 389 Wang (B39) 2021; 12 Chen (B36) 2016; 6 Quaglino (B9) 2020; 47 Teng (B37) 2015; 75 Racle (B30) 2020; 2120 de Baere (B5) 2016; 39 Oura (B12) 2021; 22 Goulet (B17) 2014; 111 Franz (B26) 2018; 46 Li (B8) 2021; 1876 Villanueva (B2) 2019; 380 Kudo (B14) 2018; 391 He (B16) 2021; 11 Llovet (B4) 2021; 7 Barsan (B11) 2020; 22 Thorsson (B28) 2019; 51 Jhunjhunwala (B35) 2021; 21 Nagy (B25) 2021; 11 Oshi (B42) 2021; 11 Ho (B32) 2020; 8 El Jabbour (B1) 2019; 25 Colwill (B24) 2011; 8 Yan (B33) 2021; 9 Steven (B7) 2016; 21 Lindberg (B21) 2013; 63 Wu (B41) 2022; 12 Becht (B31) 2016; 17 Singh (B13) 2021; 13 Zou (B22) 2014; 12 Tian (B20) 2019; 2019 von Felden (B38) 2021; 40 Szklarczyk (B27) 2021; 49 Yang (B40) 2021; 70 |
| References_xml | – volume: 173 start-page: 400 year: 2018 ident: B23 article-title: An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics publication-title: Cell doi: 10.1016/j.cell.2018.02.052 – volume: 6 year: 2016 ident: B36 article-title: Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade publication-title: Cancer Discovery doi: 10.1158/2159-8290.CD-15-1545 – volume: 11 year: 2021 ident: B42 article-title: Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer publication-title: Am J Cancer Res – volume: 8 year: 2020 ident: B32 article-title: Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma publication-title: J Immunother Cancer. doi: 10.1136/jitc-2019-000394 – volume: 17 start-page: 218 year: 2016 ident: B31 article-title: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression publication-title: Genome Biol doi: 10.1186/s13059-016-1070-5 – volume: 46 start-page: W60 year: 2018 ident: B26 article-title: GeneMANIA update 2018 publication-title: Nucleic Acids Res doi: 10.1093/nar/gky311 – volume: 25 year: 2019 ident: B1 article-title: Update on hepatocellular carcinoma: Pathologists' review publication-title: World J Gastroenterol doi: 10.3748/wjg.v25.i14.1653 – volume: 22 year: 2020 ident: B11 article-title: Immunotherapy for the treatment of acute lymphoblastic leukemia publication-title: Curr Oncol Rep doi: 10.1007/s11912-020-0875-2 – volume: 111 year: 2014 ident: B17 article-title: Comprehensive structural model of the mechanochemical cycle of a mitotic motor highlights molecular adaptations in the kinesin family publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1319848111 – volume: 70 year: 2021 ident: B40 article-title: Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-020-02711-8 – volume: 161 start-page: 55 year: 2003 ident: B19 article-title: Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A publication-title: J Cell Biol doi: 10.1083/jcb.200301026 – volume: 1876 year: 2021 ident: B8 article-title: Advances in clinical immunotherapy for gastric cancer publication-title: Biochim Biophys Acta Rev Cancer. doi: 10.1016/j.bbcan.2021.188615 – volume: 21 start-page: 298 year: 2021 ident: B35 article-title: Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion publication-title: Nat Rev Cancer. doi: 10.1038/s41568-021-00339-z – volume: 33 year: 2015 ident: B10 article-title: Immunology and immunotherapy of head and neck cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.1509 – volume: 12 year: 2014 ident: B22 article-title: Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-13-0459 – volume: 75 year: 2015 ident: B37 article-title: Classifying cancers based on T-cell infiltration and PD-L1 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0255 – volume: 13 year: 2021 ident: B13 article-title: Immunotherapy updates in advanced hepatocellular carcinoma publication-title: Cancers (Basel). doi: 10.3390/cancers13092164 – volume: 11 start-page: 6047 year: 2021 ident: B25 article-title: Pancancer survival analysis of cancer hallmark genes publication-title: Sci Rep doi: 10.1038/s41598-021-84787-5 – volume: 28 year: 2019 ident: B6 article-title: Current immunotherapy practices in melanoma publication-title: Surg Oncol Clin N Am doi: 10.1016/j.soc.2019.02.001 – volume: 11 year: 2021 ident: B16 article-title: Biomarkers and future perspectives for hepatocellular carcinoma immunotherapy publication-title: Front Oncol doi: 10.3389/fonc.2021.716844 – volume: 2019 year: 2019 ident: B20 article-title: KIF5A promotes bladder cancer proliferation in vitro and in vivo publication-title: Dis Markers doi: 10.1155/2019/4824902 – volume: 2120 year: 2020 ident: B30 article-title: EPIC: A tool to estimate the proportions of different cell types from bulk gene expression data publication-title: Methods Mol Biol doi: 10.1007/978-1-0716-0327-7_17 – volume: 12 year: 2022 ident: B41 article-title: APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival publication-title: Am J Cancer Res – volume: 22 year: 2021 ident: B12 article-title: Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review publication-title: Int J Mol Sci doi: 10.3390/ijms22115801 – volume: 7 year: 2021 ident: B4 article-title: Hepatocellular carcinoma publication-title: Nat Rev Dis Primers. doi: 10.1038/s41572-020-00240-3 – volume: 39 year: 2016 ident: B5 article-title: Treatment of liver tumors with lipiodol TACE: Technical recommendations from experts opinion publication-title: Cardiovasc Intervent Radiol doi: 10.1007/s00270-015-1208-y – volume: 37 year: 2016 ident: B34 article-title: Present yourself! by MHC class I and MHC class II molecules publication-title: Trends Immunol doi: 10.1016/j.it.2016.08.010 – volume: 40 year: 2021 ident: B38 article-title: Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/s41388-020-01519-1 – volume: 51 year: 2019 ident: B28 article-title: The immune landscape of cancer publication-title: Immunity doi: 10.1016/j.immuni.2019.08.004 – volume: 12 year: 2021 ident: B39 article-title: LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma publication-title: J Cancer. doi: 10.7150/jca.48983 – volume: 23 year: 2022 ident: B29 article-title: CAMOIP: A web server for comprehensive analysis on multi- omics of immunotherapy in pan-cancer publication-title: Brief Bioinform doi: 10.1093/bib/bbac129 – volume: 8 year: 2011 ident: B24 article-title: A roadmap to generate renewable protein binders to the human proteome publication-title: Nat Methods doi: 10.1038/nmeth.1607 – volume: 67 year: 2016 ident: B3 article-title: Liver Cancer: Connections with obesity, fatty liver, and cirrhosis publication-title: Annu Rev Med doi: 10.1146/annurev-med-090514-013832 – volume: 63 year: 2013 ident: B21 article-title: The mitochondrial and autosomal mutation landscapes of prostate cancer publication-title: Eur Urol. doi: 10.1016/j.eururo.2012.11.053 – volume: 9 year: 2021 ident: B33 article-title: Downregulated ferroptosis-related gene STEAP3 as a novel diagnostic and prognostic target for hepatocellular carcinoma and its roles in immune regulation publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2021.743046 – volume: 21 year: 2016 ident: B7 article-title: Immunotherapy for lung cancer publication-title: Respirology doi: 10.1111/resp.12789 – volume: 391 year: 2018 ident: B14 article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(18)30207-1 – volume: 49 year: 2021 ident: B27 article-title: The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa1074 – volume: 389 start-page: 56 year: 2017 ident: B15 article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32453-9 – volume: 47 year: 2020 ident: B9 article-title: Breast cancer stem cell antigens as targets for immunotherapy publication-title: Semin Immunol doi: 10.1016/j.smim.2020.101386 – volume: 88 year: 2008 ident: B18 article-title: Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics publication-title: Physiol Rev doi: 10.1152/physrev.00023.2007 – volume: 380 year: 2019 ident: B2 article-title: Hepatocellular Carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMra1713263 |
| SSID | ssj0000650103 |
| Score | 2.3239996 |
| Snippet | Liver hepatocellular carcinoma (LIHC) is one of the most common liver malignancies with high mortality and morbidity. Thus, it is crucial to identify potential... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1071722 |
| SubjectTerms | immunotherapy KIF5A liver hepatocellular carcinoma Oncology prognostic biomarker tumor microenvironment |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2AIiNxQoq6fsUxt23VVQHBiUq9WX6qlbpOtU2488-ZSdLVLkJw4RonijXfeB72-BtC3qcosxFtrJnxqZatSbUJUtUSBpTWSoWpyvdbc3YuP1-oi51WX1gTNtEDT4I78n4RmGSaRRWlabJxWUfj8OgRgnUX0PqCz9tJpiYbrLCBwXSMCVmYOcpdQcZCziFfhRSG8z1HNPL1_ynI_L1Wcsf5rB6Rh3PUSJfTbB-Te6k8Ife_zufiT8nPL59WakmHm83UWh6ETa8KvQRf03e4N4_FpjRg36DSrd1HuqSl-5GuKZZnlQ65milexMdanQ11M2QpUtympcNI8kr7Yd1t6Bor-Haux1G8kjTcPiPnq9PvJ2f13FyhDrJRfR1alVuwbY5nGaXXvGUhqcxU1AKtpzNKs5ykhgBNwoBhnHuIxRzjPrvgxXNyULqSXhLapuyV9w1LQkqFMWOUPAghpF7I7FhFFneStmFmHscGGNcWMhAExyI4FsGxMzgV-bD95Gai3fjby8cI3_ZFZMweH4Ae2VmP7L_0qCLv7sC3sMIQGldSN9xaDhlZC6m80RV5MSnD9leiaVosEq6I3lOTvbnsj5Sry5HF20CgJFr56n9M_jV5AAIR49ZQ84Yc9JshHUKw1Pu347r4BVIvFWs priority: 102 providerName: Directory of Open Access Journals |
| Title | KIF5A upregulation in hepatocellular carcinoma: A novel prognostic biomarker associated with unique tumor microenvironment status |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36686769 https://www.proquest.com/docview/2768813397 https://pubmed.ncbi.nlm.nih.gov/PMC9853384 https://doaj.org/article/bb0c14171d5d496f9af7d9a0277499ac |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HCeKL-G39OCL4JFQ3TdI0gsgqrqdyPrmwbyVJk7uD3fTstsf56H_uTNtdbmXxwZc-NAkt-WUyv5lMZgh56SsRNC-qlGnrU1Fon2onZCqgQSolpRuifL_nx3PxdSEXB2RT3mqcwPVe0w7rSc2b5eurn7_eg8C_Q4sT9O2bUEdMRphlYIqCdZLBjnwDFJNCOT0Z2f6wMUusajCcbe4fuaOd-iT--5jn3wGU1zTS7A65PVJJOh2wv0sOfLxHbp6Mh-X3ye9vX2ZySruLZqg3DwjQ80jPQAG1NTrsMQKVOiwmFOuVeUunNNaXfkkxZivWmMCZ4u18DOBpqBlx9BVF3y3t-syvtO1WdUNXGNZ37c4cxXtK3foBmc8-_fh4nI4VF1InctmmrpChgA3PZEFUwqqsYM7LwGSlOG6pRkvFghcKWJuABs2yzAJBMyyzwTjLH5LDWEf_mNDCByutzZnnQkgkkpXIHOdcqIkIhiVkspnp0o3pyLEqxrIEswTBKRGcEsEpR3AS8mo75GLIxfGvzh8Qvm1HTKPdv6ib03KUytLaiWO4UipZCZ0HbYKqtMFzbbAEjUvIiw34JYgdQmOir7t1mYGZVoB9r1VCHg2LYfspnucFRg4nRO0sk51_2W2J52d9am8N7IkX4sl_j3xKbsEs8N5JlD8jh23T-edAm1p71Lsb4Pl5wY56wfgDjDAd5g |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=KIF5A+upregulation+in+hepatocellular+carcinoma%3A+A+novel+prognostic+biomarker+associated+with+unique+tumor+microenvironment+status&rft.jtitle=Frontiers+in+oncology&rft.au=Liu%2C+Qi&rft.au=Liu%2C+Yu-yang&rft.au=Chen%2C+Xue-min&rft.au=Tao%2C+Bing-yan&rft.date=2023-01-06&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=12&rft_id=info:doi/10.3389%2Ffonc.2022.1071722&rft.externalDocID=PMC9853384 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |